BV100 (rifabutin IV) drug interaction studies in healthy subjects with index CYP450 3A probes midazolam and itraconazole
Pierre Delique, Christian Kemmer, Lisa Husband, Géza Lakner, Jürgen Jäger, Françoise Jung, Andrew F Shorr, Glenn E Dale · 2026
Read BV100 (rifabutin IV) drug interaction studies in healthy subjects with index CYP450 3A probes midazolam and itraconazole by Pierre Delique, Christian Kemmer, Lisa Husband, Géza Lakner, Jürgen Jäger, Françoise Jung, Andrew F Shorr, Glenn E Dale (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13574503.txt.
Description
Pierre Delique and seven co-authors report in 2026 two phase 1 studies of how BV100, an intravenous form of the antibiotic rifabutin, interacts with other drugs in healthy volunteers. BV100 targets serious Acinetobacter infections, a hospital scourge. Regulators require knowing whether it speeds or blocks the liver enzyme CYP3A, which clears many medicines.
One study paired BV100 with midazolam, a probe drug the enzyme clears. The other paired it with itraconazole, a strong enzyme blocker. Both pairings shifted drug levels beyond the no-effect band, confirming real interactions. Doses of partner medicines will need adjusting in patients, and the safety data gathered here shape the label for later trials.
Catalog record
| CREATOR | Pierre Delique, Christian Kemmer, Lisa Husband, Géza Lakner, Jürgen Jäger, Françoise Jung, Andrew F Shorr, Glenn E Dale |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 29 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |